BUTATABS E: Product Information

BUTATABS E- phenylbutazone tablet
Butler Animal health Supply, LLC dba Covetrus North America

Phenylbutazone Boluses

For Oral Use in Horses Only.

Non-steroidal anti-inflammatory drug (NSAID)

DESCRIPTION & PHARMACOLOGY:

Phenylbutazone chemically is 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione. It has the following structural formula:

chemical structure

Phenylbutazone was first synthesized in 1948 and introduced into human medicine in 1949, Kuzell1,2,3 , Payne4 , Fleming5 , and Denko6 , demonstrated the clinical effectiveness of phenylbutazone in gout, gouty arthritis, acute arthritis, acute rheumatism and various other rheumatoid disorders in humans. Fabre7 , Domenjoz8 , Wilhelmi9 , and Yourish10 , have established the anti-rheumatic and anti-inflammatory activity of phenylbutazone. It is entirely unrelated to the steroid hormones. Toxicity of phenylbutazone has been investigated in rats and mice11 , Ogilvie and Sutter12 , have also made a study on the chronic toxicity of phenylbutazone in dogs. They have shown that dogs receiving 10 mg. and 100 mg. per Kg. body weight, per day for 90 days, maintain good appetites, excrete normal feces, gain weight and maintain a normal blood picture. They also report no abnormal macroscopic or microscopic changes in sacrificed animals which could have been attributed to the drug. Phenylbutazone has been used by Camberos13 in thoroughbred horses. Favorable results were reported in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Results were not as favorable in the periodic treatment of osteo-arthritis of medial and distal bones of the hock, arthritis of the stifle and hip, arthrosis of the trapezious muscles, and generalized arthritis. Sutter14 reported a favorable response in chronic equine arthritis of long duration, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx.

INDICATIONS:

Phenylbutazone is for the relief of inflammatory conditons associated withthe musculoskeletal system in horses.

DOSAGE & ADMINISTRATION:

For horses only.

HORSES: Orally — 1 to 2 boluses pr 500 lb. body weight. Do not exceed 4 grams daily. Reduce dosage as symptoms regress. Intermittent treatment given only when symptoms appear may be indicated.

image of eye clockimage of eye clock

CONTRAINDICATIONS:

Use with caution in patients who have a history of drug allergy.

PRECAUTION:

Concomitant use with other antiinflammatory drugs, such as NSAIDS or corticosterioids, should be avoided or closely monitored. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently.

WARNING:

Do not use in horses intended for human consumption.

CAUTION:

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (U.S.A.) law prohibits the extra-label use of this product in female dairy cattle 20 months of age or older.

AVAILABILITY:

Available in 1 gm. boluses — 100 boluses per bottle.

REFERENCES:

1. Kuzell, W.C., Schafferzick, R.W., Naughler, W.E., Gandia, G. and Mankle, E.A.: A.M.A. Arch. Inst. Med., 92; 646 (1953).

2. Kuzell, W.C., Schafferzick, R.W., Brown, B. and Mankle, E.A.: J.A.M.A. 149; 729 (1952).

3. Kuzell, W.C., and Schafferzick, R.W.: Calif. Med. 77; 319 (1952).

4. Payne, R.W., Shelter, M.R., Farr, C.H., Hellbaum, A.A. and Ishmall, W.K.: J. Lab. Clin. Med., 45; 331 (1955).

5. Fleming, J., and Will, G.: Ann. Rheumat. Dist., 12; 95 (1953).

6. Denko, C.W., and Rumi, D.: American Pract. 6; 1865 (1956).

7. Fabre, J., et al: Semain. Hop. (Paris) 31; 87 (1955).

8. Domenjoz, R., et al: Arzneimittel-Forsch, 5;488 (1955).

9. Wilhelmi, G. and Pulver, R.: Arzneimittel-Forsch, 5; 221 (1955).

10. Yourish, W., Paton, B., Brodie, B., Burns, J.:A.M.A. Arch. Ophth., 53; 264 (1955).

11. Hazelton, L.W., Tusing, T.W. and Hollana,E.G.: J. Pharmacol. Exper. Ther., 109; 387 (1953).

12. Ogilvie, F.B. and Sutter, M.D.: Vet. Med. 52;492-4 (1957).

13. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires) 38; 9 (1956).

14. Sutter, M.D.: Vet. Med., 53; 83 (Feb. 1958).

Package Insert Issue Date: 05-09

image of LBHSOM036_i1015
(click image for full-size original)

BUTATABS E
phenylbutazone tablet
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:11695-2206
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PHENYLBUTAZONE (PHENYLBUTAZONE) PHENYLBUTAZONE 1 g
Product Characteristics
Color white (WHITE) Score 2 pieces
Shape ROUND (ROUND) Size 18mm
Flavor Imprint Code BUTE;1GM
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:11695-2206-1 12 BOTTLE, PLASTIC in 1 CASE contains a BOTTLE, PLASTIC
1 100 TABLET in 1 BOTTLE, PLASTIC This package is contained within the CASE (11695-2206-1)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANADA ANADA200433 12/01/2015 09/30/2019
Labeler — Butler Animal health Supply, LLC dba Covetrus North America (603750329)
Establishment
Name Address ID/FEI Operations
FIRST PRIORITY INCORPORATED 179925722 manufacture

Revised: 09/2019 Butler Animal health Supply, LLC dba Covetrus North America

VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. VetLabel.com provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2020. All Rights Reserved.